Relafen 750, chemically known as naproxen, represents a significant case study from a pharmacological pharmacy standpoint. It's exhibits its pain-relieving effect primarily by reducing the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin synthesis . The targeted inhibition of COX-2, compared to traditiona